Solid Tumors
Conditions
Keywords
Pancreatic Ductal Adenocarcinoma (PDAC), Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), Glioblastoma Multiforme (GBM), Anaplastic Astrocytoma (AA), Biliary Tract Carcinoma (BTC), PD-1 inhibitor, nivolumab, regorafenib, multi-kinase inhibitor
Brief summary
Researchers are looking for a better way to treat people with solid tumors. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the researchers want to learn about regorafenib taken together with nivolumab in a small number of participants with different types of tumors. These include tumors in the head and neck, the esophagus, the pancreas, the brain, and the biliary tract. The biliary tract includes gall bladder and bile ducts. The trial will include about 200 participants who are at least 18 years old. All of the participants will take 90 mg of regorafenib as a tablet by mouth. The dose of regorafenib can be adjusted up to 120 mg or down to 60 mg by the doctor based on how well a participant tolerates treatment. All of the participants will receive 480 milligrams (mg) of nivolumab through a needle put into a vein (IV infusion). The participants will take treatments in 4-week periods called cycles. They will take regorafenib once a day for 3 weeks, then stop for 1 week. In each cycle, the participants will receive nivolumab one time. These 4-week cycles will be repeated throughout the trial. The participants can take nivolumab and regorafenib until their cancer gets worse, until they have medical problems, or until they leave the trial. The longest nivolumab can be given is up to 2 years. During the trial, the doctors will take pictures of the participants' tumors using CT or MRI and will take blood and urine samples. The doctors will also do physical examinations and check the participants' heart health using an electrocardiogram (ECG). They will ask questions about how the participants are feeling and if they have any medical problems.
Interventions
DRUGRegorafenib, (Stivarga, BAY73-4506)
Intake orally, starting with 3x 30 mg tablets every day (once daily.) for 21 days of every 28-day cycle (21 days on, 7 days off). If the starting dose is well tolerated dose can be escalated to 120 mg (4x30 mg tablets).
480 mg administered on Day 1 of each treatment cycle.
Sponsors
Bristol Myers Squibb Co. and Ono Pharmaceutical Co., Ltd
Bayer
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed selected recurrent or metastatic solid tumor types that have progressed after treatment with standard therapies and for which there are no curative intent surgery or chemoradiation. * Cohort 1: subjects with HNSCC (Head and neck squamous-cell carcinoma) who have not received prior PD-1/PD-L1 inhibitor therapy. * Cohort 2: subjects with HNSCC who have progressed on or after prior systemic therapy, at least one of which included a PD-1/PD-L1 inhibitor alone or in combination with chemotherapy. * Cohort 3: subjects with ESCC (Esophageal Squamous Cell Carcinoma) who progressed on or after platinum and/or fluoropyrimidine based regimen. * Cohort 4: subjects with PDAC (Pancreatic ductal adenocarcinoma) who have progressed on or after gemcitabine or fluoropyrimidine based regimens. * Cohort 5: subjects with BTC (Biliary tract carcinoma) (intrahepatic or extrahepatic cholangiocarcinoma or gall bladder cancer) who have progressed on gemcitabine or fluoropyrimidine or platinum therapy or a combination of these agents. * Cohort 6: subjects with Grade IV GBM (Glioblastoma multiforme) or Grade III AA (Anaplastic astrocytoma) (World Health Organization \[WHO\] criteria) with unequivocal first progression after surgery followed by radiotherapy and temozolomide. * Documented HPV (Human papilloma virus) / p16 status for oropharyngeal cancer. * Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol. * Adult participants of legal maturity (18 years or older). * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 1. * Adequate hematologic and organ function as assessed by the following laboratory tests performed within 7 d before start of study treatment including: * Total bilirubin ≤1.5 x the upper limit of normal (ULN). Total bilirubin (≤3 x ULN) is allowed if Gilbert's syndrome is documented * Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤3 x ULN (≤5 x ULN for participants with liver involvement of their cancer) * Measurable disease by baseline CT or MRI per RECIST 1.1 or RANO. * Participants must consent to provide recent biopsy/tumor tissue of a primary tumor lesion or from metastases (e.g. liver, lung) for HNSCC (IO treated) for Stage 1 and 2 and in HNSCC (IO naïve) cohort for Stage 2. * Anticipated life expectancy greater than 3 months. * Be able to swallow and absorb oral tablets.
Exclusion criteria
* Presence of symptomatic central nervous system (CNS) metastases, leptomeningeal metastases or spinal cord compression. Previously-treated lesions should be stable for at least 6 weeks prior to study entry. * Participants with a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment. * Prior therapy with PD-1/PD-L1 or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, or any form of immunotherapy to treat cancer (except cohort 2). * Cohort 2: More than one prior therapy with PD-1/PD-L1 or CTLA-4 inhibitors, or any other form of immunotherapy to treat cancer. * ESCC: * patients with apparent tumor invasion on organs located adjacent to the esophageal disease (e.g., the aorta or respiratory tract). * patients who have previously received taxane agents for recurrent/metastatic cancer. * GBM/AA * Primary tumors localized to the brainstem or spinal cord. * Presence of diffuse leptomeningeal disease or extracranial disease. * Participants requiring \> 4 mg of dexamethasone or biologic equivalent per day to control symptoms related to brain tumor and cerebral edema within 21 days of starting study treatment. * Participants who have known dMMR/MSI-H cancers or NTRK (tropomyosin receptor kinase) fusions. * Prior therapy with regorafenib. * Systemic anti-cancer treatment within 14 days or less than 5 half-lives (whichever is shorter) of the first dose of study treatment. * Participants who have permanent discontinuation of PD-1/PD-L1 therapy due to toxicity. * Arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks) within 6 months before the start of study treatment. Active pulmonary emboli or deep vein thrombosis that are significant or not adequately controlled on anticoagulation regimen as per investigator's judgement. * History of cardiac disorders as defined by: * Congestive heart failure ≥ New York Heart Association (NYHA) class 2: * Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months), myocardial infarction less than 6 months before start of study drug. * Uncontrolled cardiac arrhythmias. * Poorly controlled hypertension, defined as a blood pressure consistently above 140/90 mmHg despite optimal medical management. * Participants with an active, known or suspected autoimmune disease. * History of (non-infectious) pneumonitis that required steroids, current pneumonitis or interstitial lung disease. * Active infection \> NCI-CTCAE Grade 2. * Positive test (from historical data or tested during screening) for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). * Any positive test result for hepatitis B virus (HBV) or hepatitis C virus (HCV) indicating presence of virus, e.g. Hepatitis B surface antigen (HBsAg, Australia antigen) positive (except for participants on anti-viral therapy for HBV with a viral load \< 100 IU/mL), or Hepatitis C antibody (anti-HCV) positive (except if HCV-ribonucleic acid \[RNA\] negative). * Pregnancy or breast feeding. * Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation. * History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial or interfere with the participation for the full duration of the trial. * Participants with a current or past history of interstitial lung disease or pulmonary fibrosis diagnosed based on imaging or clinical findings.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) | From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months | Tumor response was evaluated as ORR per RECIST 1.1 by local assessments for all tumor types, except for GBM/AA, where ORR per RANO by local assessment was used. ORR was defined as the proportion of participants with best overall response of complete response (CR) or partial response (PR). Participants for whom best overall tumor response was not CR or PR, as well as participants without any post-baseline tumor assessment were considered non-responders. Descriptive statistics were done, no inferential statistical analyses were performed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Control Rate (DCR) | From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months | CR = Complete response; PR = Partial response; SD = Stable disease |
| Progression Free Survival (PFS) | From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months | PFS was defined as the time (in days) from the start of study intervention to the date of first objectively documented progressive disease (PD) or death from any cause (if no progression was documented). |
| 6 Months PFS | Up to last participant follow 6 months (approximately 22 months) | 6 Months PFS rate |
| Duration of Response (DOR) | From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months | Defined as the time (in days) from the first documented objective response of PR or CR, whichever is noted earlier, to disease progression or death (if death occurs before progression is documented). DOR will be defined for responders only, i.e. participants with a CR or PR. |
| 1 Year OS | From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 month] | — |
| Number of Participants With Adverse Events | Up to the last participant has been followed for approximately 10 months, summed up to approximately 26 months | AEs were considered to be treatment-emergent (TEAEs) if they started or worsened after the start of first study drug administration until 30 days after regorafenib treatment discontinuation or 100 days after the last dose of nivolumab, whatever occurred later. |
| Overall Survival (OS) | From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months | OS was defined as the time (in days) from the start of study intervention to the date of death due to any cause. |
Countries
Belgium, France, Italy, Japan, South Korea, Taiwan, United Kingdom, United States
Participant flow
Recruitment details
The study was conducted at 34 study centers in 8 countries/regions from 03 February 2021 (first patient first visit) to 29 March 2024 (last patient last visit)
Pre-assignment details
175 participants were enrolled and received study treatment. Participants were enrolled in 6 cohorts: HNSCC IO naïve (N=30), HNSCC IO treated (N=20), ESCC (N=30), PDAC (N=20), BTC (N=45), and GBM/AA (N=30)
Participants by arm
| Arm | Count |
|---|---|
| HNSCC (IO Naive) Participants with confirmed recurrent or metastatic HNSCC and IO naive, received regorafenib in combination with nivolumab. (treatment details refers to Description under Participant Flow section above) | 30 |
| HNSCC (IO Treated) Participants with confirmed recurrent or metastatic HNSCC and with IO treated, received regorafenib in combination with nivolumab. (treatment details refers to Description under Participant Flow section above) | 20 |
| ESCC Participants with confirmed recurrent or metastatic ESCC received regorafenib in combination with nivolumab. (treatment details refers to Description under Participant Flow section above) | 30 |
| PDAC Participants with confirmed recurrent or metastatic PADC received regorafenib in combination with nivolumab. (treatment details refers to Description under Participant Flow section above) | 20 |
| Biliary Tract Cancer (BTC) Participants with confirmed recurrent or metastatic BTC received regorafenib in combination with nivolumab. (treatment details refers to Description under Participant Flow section above) | 45 |
| GBM/AA Participants with GBM or AA received regorafenib in combination with nivolumab. (treatment details refers to Description under Participant Flow section above) | 30 |
| Total | 175 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 3 | 2 | 4 | 2 | 3 | 0 |
| Overall Study | Completed max. allowed treatment. A max. of 24 infusions of Nivolumab were allowed for participants | 2 | 0 | 1 | 0 | 1 | 0 |
| Overall Study | Death | 3 | 0 | 0 | 0 | 3 | 0 |
| Overall Study | Participant Decision | 1 | 1 | 0 | 0 | 0 | 0 |
| Overall Study | Patient continued in rollover study for regorafenib | 1 | 0 | 4 | 0 | 0 | 0 |
| Overall Study | Physician Decision | 1 | 0 | 1 | 0 | 2 | 0 |
| Overall Study | Progressive Disease | 19 | 17 | 20 | 18 | 36 | 30 |
Baseline characteristics
| Characteristic | HNSCC (IO Naive) | Total | GBM/AA | Biliary Tract Cancer (BTC) | PDAC | ESCC | HNSCC (IO Treated) |
|---|---|---|---|---|---|---|---|
| Age, Customized 65-<75 years | 12 Participants | 63 Participants | 7 Participants | 22 Participants | 7 Participants | 11 Participants | 4 Participants |
| Age, Customized <65 years | 16 Participants | 95 Participants | 22 Participants | 17 Participants | 13 Participants | 17 Participants | 10 Participants |
| Age, Customized 75-<85 years | 2 Participants | 17 Participants | 1 Participants | 6 Participants | 0 Participants | 2 Participants | 6 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 15 Participants | 65 Participants | 2 Participants | 11 Participants | 5 Participants | 21 Participants | 11 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 9 Participants | 24 Participants | 2 Participants | 6 Participants | 2 Participants | 2 Participants | 3 Participants |
| Race (NIH/OMB) White | 6 Participants | 85 Participants | 26 Participants | 27 Participants | 13 Participants | 7 Participants | 6 Participants |
| Sex: Female, Male Female | 5 Participants | 55 Participants | 10 Participants | 20 Participants | 11 Participants | 3 Participants | 6 Participants |
| Sex: Female, Male Male | 25 Participants | 120 Participants | 20 Participants | 25 Participants | 9 Participants | 27 Participants | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 22 / 30 | 17 / 20 | 20 / 30 | 17 / 20 | 36 / 45 | 27 / 30 |
| other Total, other adverse events | 30 / 30 | 20 / 20 | 30 / 30 | 20 / 20 | 45 / 45 | 29 / 30 |
| serious Total, serious adverse events | 22 / 30 | 15 / 20 | 19 / 30 | 13 / 20 | 28 / 45 | 13 / 30 |
Outcome results
Primary
Overall Response Rate (ORR)
Tumor response was evaluated as ORR per RECIST 1.1 by local assessments for all tumor types, except for GBM/AA, where ORR per RANO by local assessment was used. ORR was defined as the proportion of participants with best overall response of complete response (CR) or partial response (PR). Participants for whom best overall tumor response was not CR or PR, as well as participants without any post-baseline tumor assessment were considered non-responders. Descriptive statistics were done, no inferential statistical analyses were performed.
Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months
Population: FAS: all participants who received study treatment were included in the full analysis set
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HNSCC (IO Naive) | Overall Response Rate (ORR) | 6 Participants |
| HNSCC (IO Treated) | Overall Response Rate (ORR) | 1 Participants |
| ESCC | Overall Response Rate (ORR) | 15 Participants |
| PDAC | Overall Response Rate (ORR) | 0 Participants |
| Biliary Tract Cancer (BTC) | Overall Response Rate (ORR) | 2 Participants |
| GBM/AA | Overall Response Rate (ORR) | 1 Participants |
Secondary
1 Year OS
Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 month]
Population: FAS: all participants who received study treatment were included in the full analysis set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| HNSCC (IO Naive) | 1 Year OS | 0.415 Proportion of participants |
| HNSCC (IO Treated) | 1 Year OS | 0.444 Proportion of participants |
| ESCC | 1 Year OS | 0.764 Proportion of participants |
| PDAC | 1 Year OS | 0.281 Proportion of participants |
| Biliary Tract Cancer (BTC) | 1 Year OS | 0.422 Proportion of participants |
| GBM/AA | 1 Year OS | 0.337 Proportion of participants |
Secondary
6 Months PFS
6 Months PFS rate
Time frame: Up to last participant follow 6 months (approximately 22 months)
Population: FAS: all participants who received study treatment were included in the full analysis set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| HNSCC (IO Naive) | 6 Months PFS | 0.455 Proportion of participants |
| HNSCC (IO Treated) | 6 Months PFS | 0.263 Proportion of participants |
| ESCC | 6 Months PFS | 0.533 Proportion of participants |
| PDAC | 6 Months PFS | 0.050 Proportion of participants |
| Biliary Tract Cancer (BTC) | 6 Months PFS | 0.148 Proportion of participants |
| GBM/AA | 6 Months PFS | 0.167 Proportion of participants |
Secondary
Disease Control Rate (DCR)
CR = Complete response; PR = Partial response; SD = Stable disease
Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months
Population: FAS: all participants who received study treatment were included in the full analysis set
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HNSCC (IO Naive) | Disease Control Rate (DCR) | 16 Participants |
| HNSCC (IO Treated) | Disease Control Rate (DCR) | 13 Participants |
| ESCC | Disease Control Rate (DCR) | 22 Participants |
| PDAC | Disease Control Rate (DCR) | 7 Participants |
| Biliary Tract Cancer (BTC) | Disease Control Rate (DCR) | 24 Participants |
| GBM/AA | Disease Control Rate (DCR) | 10 Participants |
Secondary
Duration of Response (DOR)
Defined as the time (in days) from the first documented objective response of PR or CR, whichever is noted earlier, to disease progression or death (if death occurs before progression is documented). DOR will be defined for responders only, i.e. participants with a CR or PR.
Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months
Population: Subgroup of participants that had a best overall response of CR or PR that had received the study treatment
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| HNSCC (IO Naive) | Duration of Response (DOR) | NA Days |
| HNSCC (IO Treated) | Duration of Response (DOR) | NA Days |
| ESCC | Duration of Response (DOR) | 420 Days |
| Biliary Tract Cancer (BTC) | Duration of Response (DOR) | 432 Days |
| GBM/AA | Duration of Response (DOR) | 140 Days |
Secondary
Number of Participants With Adverse Events
AEs were considered to be treatment-emergent (TEAEs) if they started or worsened after the start of first study drug administration until 30 days after regorafenib treatment discontinuation or 100 days after the last dose of nivolumab, whatever occurred later.
Time frame: Up to the last participant has been followed for approximately 10 months, summed up to approximately 26 months
Population: Safety analysis set (SAF): all participants who received study treatment were included in the safety analysis set. As the safety analysis set equals the full analysis, all safety related analysis were performed on the full analysis set.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HNSCC (IO Naive) | Number of Participants With Adverse Events | Any AE | 30 Participants |
| HNSCC (IO Naive) | Number of Participants With Adverse Events | Worst grade: Grade 1 | 1 Participants |
| HNSCC (IO Naive) | Number of Participants With Adverse Events | Worst grade: Grade 2 | 4 Participants |
| HNSCC (IO Naive) | Number of Participants With Adverse Events | Worst grade: Grade 3 | 16 Participants |
| HNSCC (IO Naive) | Number of Participants With Adverse Events | Worst grade: Grade 4 | 6 Participants |
| HNSCC (IO Naive) | Number of Participants With Adverse Events | Worst grade: Grade 5 (death) | 3 Participants |
| HNSCC (IO Treated) | Number of Participants With Adverse Events | Worst grade: Grade 1 | 0 Participants |
| HNSCC (IO Treated) | Number of Participants With Adverse Events | Worst grade: Grade 3 | 16 Participants |
| HNSCC (IO Treated) | Number of Participants With Adverse Events | Worst grade: Grade 5 (death) | 1 Participants |
| HNSCC (IO Treated) | Number of Participants With Adverse Events | Any AE | 20 Participants |
| HNSCC (IO Treated) | Number of Participants With Adverse Events | Worst grade: Grade 2 | 1 Participants |
| HNSCC (IO Treated) | Number of Participants With Adverse Events | Worst grade: Grade 4 | 2 Participants |
| ESCC | Number of Participants With Adverse Events | Worst grade: Grade 5 (death) | 2 Participants |
| ESCC | Number of Participants With Adverse Events | Worst grade: Grade 4 | 2 Participants |
| ESCC | Number of Participants With Adverse Events | Worst grade: Grade 3 | 18 Participants |
| ESCC | Number of Participants With Adverse Events | Worst grade: Grade 2 | 6 Participants |
| ESCC | Number of Participants With Adverse Events | Any AE | 30 Participants |
| ESCC | Number of Participants With Adverse Events | Worst grade: Grade 1 | 2 Participants |
| PDAC | Number of Participants With Adverse Events | Worst grade: Grade 3 | 11 Participants |
| PDAC | Number of Participants With Adverse Events | Worst grade: Grade 1 | 0 Participants |
| PDAC | Number of Participants With Adverse Events | Worst grade: Grade 2 | 2 Participants |
| PDAC | Number of Participants With Adverse Events | Worst grade: Grade 5 (death) | 5 Participants |
| PDAC | Number of Participants With Adverse Events | Worst grade: Grade 4 | 2 Participants |
| PDAC | Number of Participants With Adverse Events | Any AE | 20 Participants |
| Biliary Tract Cancer (BTC) | Number of Participants With Adverse Events | Any AE | 45 Participants |
| Biliary Tract Cancer (BTC) | Number of Participants With Adverse Events | Worst grade: Grade 4 | 1 Participants |
| Biliary Tract Cancer (BTC) | Number of Participants With Adverse Events | Worst grade: Grade 1 | 1 Participants |
| Biliary Tract Cancer (BTC) | Number of Participants With Adverse Events | Worst grade: Grade 2 | 9 Participants |
| Biliary Tract Cancer (BTC) | Number of Participants With Adverse Events | Worst grade: Grade 3 | 23 Participants |
| Biliary Tract Cancer (BTC) | Number of Participants With Adverse Events | Worst grade: Grade 5 (death) | 11 Participants |
| GBM/AA | Number of Participants With Adverse Events | Worst grade: Grade 3 | 11 Participants |
| GBM/AA | Number of Participants With Adverse Events | Worst grade: Grade 2 | 8 Participants |
| GBM/AA | Number of Participants With Adverse Events | Worst grade: Grade 4 | 2 Participants |
| GBM/AA | Number of Participants With Adverse Events | Worst grade: Grade 5 (death) | 9 Participants |
| GBM/AA | Number of Participants With Adverse Events | Worst grade: Grade 1 | 0 Participants |
| GBM/AA | Number of Participants With Adverse Events | Any AE | 30 Participants |
Secondary
Overall Survival (OS)
OS was defined as the time (in days) from the start of study intervention to the date of death due to any cause.
Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months
Population: FAS: all participants who received study treatment were included in the full analysis set
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| HNSCC (IO Naive) | Overall Survival (OS) | 358 Days |
| HNSCC (IO Treated) | Overall Survival (OS) | 355 Days |
| ESCC | Overall Survival (OS) | 627 Days |
| PDAC | Overall Survival (OS) | 259 Days |
| Biliary Tract Cancer (BTC) | Overall Survival (OS) | 246 Days |
| GBM/AA | Overall Survival (OS) | 245 Days |
Secondary
Progression Free Survival (PFS)
PFS was defined as the time (in days) from the start of study intervention to the date of first objectively documented progressive disease (PD) or death from any cause (if no progression was documented).
Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months
Population: FAS: all participants who received study treatment were included in the full analysis set
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| HNSCC (IO Naive) | Progression Free Survival (PFS) | 79 Days |
| HNSCC (IO Treated) | Progression Free Survival (PFS) | 105 Days |
| ESCC | Progression Free Survival (PFS) | 259 Days |
| PDAC | Progression Free Survival (PFS) | 53 Days |
| Biliary Tract Cancer (BTC) | Progression Free Survival (PFS) | 98 Days |
| GBM/AA | Progression Free Survival (PFS) | 55 Days |